| Primary |
| Prostate Cancer Metastatic |
92.8% |
| Prostate Cancer |
3.6% |
| Diabetes Mellitus |
0.4% |
| Hypertension |
0.4% |
| Indwelling Catheter Management |
0.4% |
| Nausea |
0.3% |
| Pain |
0.3% |
| Constipation |
0.2% |
| Oedema |
0.2% |
| Product Used For Unknown Indication |
0.2% |
| Rheumatoid Arthritis |
0.2% |
| Sedation |
0.2% |
| Prostate Cancer |
0.1% |
| Prostate Cancer Metastatic |
0.1% |
| Anxiety |
0.1% |
| Atrial Fibrillation |
0.1% |
| Chills |
0.1% |
| Deep Vein Thrombosis |
0.1% |
| Gastritis Erosive |
0.1% |
| Insomnia |
0.1% |
|
| Chills |
9.3% |
| Death |
7.5% |
| Hospitalisation |
7.2% |
| Infusion Related Reaction |
6.1% |
| Malaise |
5.7% |
| Vomiting |
5.7% |
| Myocardial Infarction |
5.4% |
| Cerebrovascular Accident |
5.0% |
| Fatigue |
4.7% |
| Hypotension |
4.7% |
| Disease Progression |
4.3% |
| Fall |
4.3% |
| Pneumonia |
4.3% |
| Transient Ischaemic Attack |
4.3% |
| Adverse Event |
3.9% |
| Prostate Cancer |
3.6% |
| Prostate Cancer Metastatic |
3.6% |
| Pyrexia |
3.6% |
| Urinary Tract Infection |
3.6% |
| Asthenia |
3.2% |
|
| Secondary |
| Prostate Cancer Metastatic |
73.2% |
| Product Used For Unknown Indication |
11.3% |
| Prostate Cancer |
8.0% |
| Pain |
1.3% |
| Indwelling Catheter Management |
0.8% |
| Metastatic Neoplasm |
0.8% |
| Metastases To Prostate |
0.5% |
| Myelopathy |
0.5% |
| Chills |
0.4% |
| Diabetes Mellitus |
0.4% |
| Hormone Therapy |
0.4% |
| Nausea |
0.4% |
| Atrial Fibrillation |
0.3% |
| Deep Vein Thrombosis |
0.3% |
| Hypersensitivity |
0.3% |
| Hypertension |
0.3% |
| Pulmonary Embolism |
0.3% |
| Urinary Tract Infection |
0.3% |
| Antiemetic Supportive Care |
0.1% |
| Anxiety |
0.1% |
|
| Death |
9.4% |
| Hospitalisation |
8.2% |
| Chills |
6.4% |
| Infusion Related Reaction |
6.4% |
| Transient Ischaemic Attack |
6.4% |
| Myocardial Infarction |
5.8% |
| Cerebrovascular Accident |
5.3% |
| Haemorrhage Intracranial |
4.7% |
| Pyrexia |
4.7% |
| Arthralgia |
4.1% |
| Disease Progression |
4.1% |
| Fall |
4.1% |
| Fatigue |
4.1% |
| Prostate Cancer Metastatic |
4.1% |
| Thrombocytopenia |
4.1% |
| Thrombosis |
4.1% |
| Adverse Event |
3.5% |
| Asthenia |
3.5% |
| Gastrointestinal Haemorrhage |
3.5% |
| Neoplasm Progression |
3.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
25.0% |
| Prostate Cancer |
25.0% |
| Prostate Cancer Metastatic |
14.3% |
| Metastases To Bone |
12.5% |
| Infusion Related Reaction |
7.1% |
| Osteoporosis |
3.6% |
| Type 2 Diabetes Mellitus |
3.6% |
| Gastrooesophageal Reflux Disease |
1.8% |
| Hot Flush |
1.8% |
| Hyperlipidaemia |
1.8% |
| Hypertension |
1.8% |
| Prophylaxis |
1.8% |
|
| Back Pain |
8.3% |
| Fall |
8.3% |
| Hypocalcaemia |
8.3% |
| Osteonecrosis Of Jaw |
8.3% |
| Blood Alkaline Phosphatase Increased |
4.2% |
| Brain Injury |
4.2% |
| Dental Caries |
4.2% |
| Diarrhoea |
4.2% |
| Disease Progression |
4.2% |
| Malaise |
4.2% |
| Memory Impairment |
4.2% |
| Myocardial Infarction |
4.2% |
| Nausea |
4.2% |
| Neoplasm Malignant |
4.2% |
| Pain In Jaw |
4.2% |
| Prostate Cancer Metastatic |
4.2% |
| Syncope |
4.2% |
| Toothache |
4.2% |
| Tremor |
4.2% |
| Weight Decreased |
4.2% |
|
